Premium
KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88 MT LYMPHOMA MODELS
Author(s) -
Mayo M,
Karnik R,
Klaus C,
Sharma K,
McDonald A,
Walker D. H,
Weiss M
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.13_2879
Subject(s) - cancer research , chemistry , ibrutinib , pharmacology , medicine , immunology , chronic lymphocytic leukemia , leukemia